Diffusion Pharmaceuticals, Inc.

US initial public offerings by biopharmaceutical companies appear to be on the rise in 2024 with nine during the first quarter, including Boundless Bio Inc. ’s $100m IPO on 27 March, outpacing 2023 w

Private biotech EIP Pharma, Inc. and publicly traded Diffusion Pharmaceuticals, Inc. are entering an all-stock merger to create a new firm focused on CNS therapeutics with an eye to bringing the f

Many public biopharmaceutical companies have turned to alternatives other than follow-on public offerings (FOPOs) this year to fund their research and development programs while stock prices have been

IN VITRO DIAGNOSTICS Financings HTG Molecular Diagnostics Inc. HTG Molecular Diagnostics Inc. netted $37.9mm through a public offering of 13.9mm common shares (including the overallotment) at $2.9